Trial Profile

An International, Open Label, Randomised Controlled Trial Comparing Rituximab With Azathioprine as Maintenance Therapy in Relapsing ANCA-associated Vasculitis

Status: Completed

Phase of Trial: Phase III

Latest Information Update: 28 Mar 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Rituximab (Primary) ; Azathioprine; Glucocorticoids; Methotrexate; Methotrexate; Methotrexate; Mycophenolate mofetil
Indications Anti-neutrophil cytoplasmic antibody-associated vasculitis
Focus Registrational; Therapeutic Use
Acronyms RITAZAREM

Most Recent Events

23 Mar 2023 Results published in the Annals of the Rheumatic Diseases.
06 Jun 2020 Results assessing effect of rituximab from this study, presented at the 21st Annual Congress of the European League Against Rheumatism
27 Feb 2020 Status changed from active, no longer recruiting to completed.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com